News from lipocine inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 11, 2021, 08:00 ET Lipocine Announces Financial Results For The Year Ended December 31, 2020

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial...

Mar 11, 2021, 08:00 ET Lipocine To Present At M Vest / Maxim Conference And At The Lytham Partners Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the...

Mar 04, 2021, 08:00 ET Lipocine Announces Publication in Journal of Endocrinological Investigation Highlighting the Potential of LPCN 1144 in the Treatment of NASH and Hepatic Fibrosis

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the...

Mar 03, 2021, 08:00 ET Lipocine Announces Presentations on TLANDO™ at ENDO 2021 Conference

Lipocine Inc. (Nasdaq: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that clinical...

Feb 26, 2021, 08:00 ET Lipocine to Present at Two Upcoming Investor Conferences

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the...

Jan 28, 2021, 16:00 ET Lipocine Closes Underwritten Public Offering Of Common Stock

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of...

Jan 26, 2021, 09:00 ET Lipocine Prices $25 Million Underwritten Public Offering Of Common Stock

Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of...

Jan 25, 2021, 16:00 ET Lipocine Announces Launch Of Public Offering Of Common Stock

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it...

Jan 14, 2021, 08:00 ET Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the...

Jan 12, 2021, 08:00 ET Lipocine Announces Positive Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced positive...

Jan 04, 2021, 08:00 ET Lipocine to Present at the H.C. Wainwright BioConnect 2021 Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced that the Company...

Dec 30, 2020, 08:00 ET Lipocine Announces Open Label Extension to Ongoing LPCN 1144 LiFT Study

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it is...

Dec 29, 2020, 08:00 ET Lipocine Announces Update on Jury Trial in Patent Infringement Lawsuit Against Clarus Therapeutics

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that Judge...

Dec 08, 2020, 20:49 ET Lipocine Announces Tentative Approval of TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S....

Dec 08, 2020, 20:40 ET Lipocine Announces Deletion of Unauthorized Changes to Company's Website

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an...

Dec 04, 2020, 17:45 ET Lipocine Provides New Regulatory Update on TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S....

Nov 10, 2020, 08:00 ET Lipocine Announces Third Quarter 2020 Financial and Operational Results

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial...

Nov 06, 2020, 08:00 ET Lipocine Provides Regulatory Update on TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S....

Nov 05, 2020, 08:00 ET Lipocine to Present Preclinical Data on Therapeutic Potential of LPCN 1144 in Hepatic Fibrosis and NASH at The Liver Meeting Digital Experience™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will...

Oct 14, 2020, 08:00 ET Lipocine Announces Presentations at the 21st Annual Fall Meeting of the Sexual Medicine Society of North America

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced it will...

Sep 29, 2020, 08:00 ET Lipocine to Present at the H.C. Wainwright 4th Annual NASH Investor Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, will provide an update on LPCN ...

Sep 21, 2020, 08:00 ET Lipocine Announces Completion of Enrollment in the LPCN 1144 LiFT Study

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the last...

Sep 08, 2020, 08:00 ET Lipocine to Participate in HC Wainwright Annual Global Investment Conference

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it will...

Aug 28, 2020, 16:00 ET Lipocine Provides Regulatory Update for TLANDO™

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S....

Aug 06, 2020, 08:00 ET Lipocine Announces Second Quarter 2020 Financial and Operational Results

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial...